River Vision
Developed a biologic to treat the orphan eye disorder Graves Orbitopathy, a very debilitating condition that ultimately can lead to blindness.
Launch date
Market cap
-
Enterprise valuation
$145m (Public information from May 2017)
New York City New York (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$17.0m | Series A | ||
$145m Valuation: $145m | Acquisition | ||
| Total Funding | $17.0m | ||